All In MedTech

Device Trial Radar · NCT06214221

Using Signos mHealth Platform in Adults for Weight Management

A Randomized Controlled Trial Evaluating the Safety and Effectiveness of the Intelligently-Driven Signos System for Personalized Weight Management in Overweight and Obese Adults

Last checked: Nov 20, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

380

Actual

Start

Jan 2, 2024

Primary completion

Dec 31, 2024

Study completion Apr 30, 2026

Sponsor

Lead sponsor
Signos IncNot on our public-company list
Sponsor type
Industry
Collaborators
Lindus Health, Inc.
First posted
Jan 19, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Metabolic syndrome and resulting downstream health effects remains a growing health concern. In published trials, the use of continuous glucose monitoring (CGM) assists behavioral changes efforts, leading to improved adherence and results from diet and exercise changes in individuals with obesity. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools that help participants in the pursuit of weight change goals. The investigators hypothesize that the use of CGM data and targeted coaching and nutrition education will assist with weight optimization goals in the general (non-diabetic) population using the Signos mHealth platform, with associated health benefits.

Conditions

  • Overweight and Obesity
  • Metabolic Syndrome
  • Weight Loss

Interventions

  • Signos SystemDevice

    The intervention involves the use of the Signos System, a combination of a proprietary software application with a continuous glucose monitor (CGM), to manage weight in overweight and obese adults.

  • Standard Lifestyle EducationOther

    In the "Standard Lifestyle Education" arm, participants receive conventional advice on diet and exercise, focusing on general healthy lifestyle habits to manage weight.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Responder RateTime frame: 6 Months
  2. Average Total Body Weight Loss (TBWL%)Time frame: 6 Months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Helios Clinical Research (Phoenix)

    Phoenix, Arizona

  • Diablo Clinical Research

    Walnut Creek, California

  • Segal Trials

    North Miami, Florida

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.